Abstract:Primary osteoporosis is closely linked to hormone deficiency, which disrupts the balance of bone remodeling. It affects postmenopausal women but also significantly impacts older men. Estrogen can promote the production of osteoprotegerin, a decoy receptor for RANKL, thereby preventing RANKL from activating osteoclasts. Furthermore, estrogen promotes osteoblast survival and function via activation of the Wnt signaling pathway. Likewise, androgens play a critical role in bone metabolism, primarily through their conversion to estrogen in men. Estrogen deficiency accelerates bone resorption through a rise in pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and RANKL, which promote osteoclastogenesis. In the classic genomic pathway, estrogen binds to estrogen receptors in the cytoplasm, forming a complex that migrates to the nucleus and binds to estrogen response elements on DNA, regulating gene transcription. Androgens can be defined as high-affinity ligands for the androgen receptor; their combination can serve as a ligand-inducible transcription factor. Hormone replacement therapy has shown promise but comes with associated risks and side effects. In contrast, the non-genomic pathway involves rapid signaling cascades initiated at the cell membrane, influencing cellular functions without directly altering gene expression. Therefore, the ligand-independent actions and rapid signaling pathways of estrogen and androgen receptors can be harnessed to develop new drugs that provide bone protection without the side effects of traditional hormone therapies. To manage primary osteoporosis, other pharmacological treatments (bisphosphonates, teriparatide, RANKL inhibitors, sclerostin inhibitors, SERMs, and calcitonin salmon) can ameliorate osteoporosis and improve BMD via actions on different pathways. Non-pharmacological treatments include nutritional support and exercise, as well as the dietary intake of antioxidants and natural products. The current study reviews the processes of bone remodeling, hormone actions, hormone receptor status, and therapeutic targets of primary osteoporosis. However, many detailed cellular and molecular mechanisms underlying primary osteoporosis seem complicated and unexplored and warrant further investigation.

Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly

Hormonal Control of Bone Architecture Throughout the Lifespan: Implications for Fracture Prediction and Prevention

T-Cell Mediated Inflammation in Postmenopausal Osteoporosis

Sequential management of postmenopausal health and osteoporosis: An update

Ovarian Aging and Osteoporosis.

Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people

Endocrine, Metabolic, and Immune Pathogenesis of Postmenopausal Osteoporosis. Is there a Therapeutic Role in Natural Products?

An update for the obstetrician-gynecologist on advances in the diagnosis, prevention, and treatment of postmenopausal osteoporosis

Senescent Cells: A Therapeutic Target for Osteoporosis

Androgens, cardiovascular disease and osteoporosis

Targeting Aging with the Healthy Skeletal System: the Endocrine Role of Bone

Bone Aging, Cellular Senescence, and Osteoporosis

Neuroendocrinology of bone

An in silico approach to elucidate the pathways leading to primary osteoporosis: age-related vs. postmenopausal

The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments

The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male Primary Osteoporosis

Aging and Bone Metabolism

The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go

Secondary osteoporosis - an endocrinological approach focusing on underlying mechanisms

Age Related Osteoporosis: Targeting Cellular Senescence

Possible mechanisms underlying the regulation of postmenopausal osteoporosis by follicle-stimulating hormone